SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

1. Redin, E.
2. Garmendia, I.
3. Lozano, T.
4. Serrano, D.
5. Senent, Y.
6. Redrado, M.
7. Villalba, M.
8. De Andrea, C.E.
9. Exposito, F.
10. Ajona, D.
11. Ortiz-Espinosa, S.
12. Remirez, A.
13. Bertolo, C.
14. Sainz, C.
15. Garcia-Pedrero, J.
16. Pio, R.
17. Lasarte, J.
18. Agorreta, J.
19. Montuenga, L.M.
20. Calvo, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1136/JITC-2020-001496 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus